Proteasome inhibition circumvents solid tumor resistance to topoisomerase II-directed drugs
- PMID: 10811120
Proteasome inhibition circumvents solid tumor resistance to topoisomerase II-directed drugs
Abstract
Physiological cell conditions, such as glucose deprivation and hypoxia, play a role in developing drug resistance in solid tumors. These tumor-specific conditions cause decreased expression of DNA topoisomerase IIalpha (topo IIalpha), rendering cells resistant to topo II-targeted drugs, such as etoposide and doxorubicin. We show here that inhibition of proteasome attenuated drug resistance by inhibiting topo IIalpha depletion induced by glucose starvation and hypoxia. topo IIalpha restoration was seen only at the protein levels, indicating that the topo IIalpha protein depletion occurred through a proteasome-mediated degradation mechanism. The stress-induced etoposide resistance was effectively prevented in vitro by the proteasome inhibitor lactacystin in both intrinsically resistant and sensitive tumor cells (colon cancer HT-29 and ovarian cancer A2780 cells, respectively). Furthermore, lactacystin effectively enhanced the antitumor activity of etoposide in the refractory HT-29 xenograft. These results indicate that lactacystin could serve as a new therapeutic agent to circumvent resistance to topo II-targeted chemotherapy in solid tumors.
Similar articles
-
Role of proteasomal degradation in the cell cycle-dependent regulation of DNA topoisomerase IIalpha expression.Biochem Pharmacol. 2001 Apr 1;61(7):795-802. doi: 10.1016/s0006-2952(01)00580-9. Biochem Pharmacol. 2001. PMID: 11274964
-
Glucose-regulated stresses cause degradation of DNA topoisomerase IIalpha by inducing nuclear proteasome during G1 cell cycle arrest in cancer cells.J Cell Physiol. 1999 Jul;180(1):97-104. doi: 10.1002/(SICI)1097-4652(199907)180:1<97::AID-JCP11>3.0.CO;2-Y. J Cell Physiol. 1999. PMID: 10362022
-
Nuclear localization of proteasomes participates in stress-inducible resistance of solid tumor cells to topoisomerase II-directed drugs.Cancer Res. 2002 Sep 1;62(17):5008-12. Cancer Res. 2002. PMID: 12208754
-
Lactacystin, proteasome function, and cell fate.J Biol Chem. 1998 Apr 10;273(15):8545-8. doi: 10.1074/jbc.273.15.8545. J Biol Chem. 1998. PMID: 9535824 Review. No abstract available.
-
Clinical resistance to topoisomerase-targeted drugs.Biochim Biophys Acta. 1998 Oct 1;1400(1-3):275-88. doi: 10.1016/s0167-4781(98)00141-9. Biochim Biophys Acta. 1998. PMID: 9748627 Review.
Cited by
-
Antioxidative and anticancer activity of extracts of cherry (Prunus serrulata var. spontanea) blossoms.Plant Foods Hum Nutr. 2007 Jun;62(2):79-84. doi: 10.1007/s11130-007-0045-9. Epub 2007 Jun 19. Plant Foods Hum Nutr. 2007. PMID: 17577669
-
Lactacystin exhibits potent anti-tumor activity in an animal model of malignant glioma when administered via controlled-release polymers.J Neurooncol. 2006 May;77(3):225-32. doi: 10.1007/s11060-005-6937-3. J Neurooncol. 2006. PMID: 16609837 Free PMC article.
-
Proteomic Assessment of Extracellular Vesicles from Canine Tissue Explants as a Pipeline to Identify Molecular Targets in Osteosarcoma: PSMD14/Rpn11 as a Proof of Principle.Int J Mol Sci. 2022 Mar 17;23(6):3256. doi: 10.3390/ijms23063256. Int J Mol Sci. 2022. PMID: 35328679 Free PMC article.
-
Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal.Cancer Sci. 2003 Jan;94(1):15-21. doi: 10.1111/j.1349-7006.2003.tb01345.x. Cancer Sci. 2003. PMID: 12708468 Free PMC article. Review.
-
Enzymatic Processing of DNA-Protein Crosslinks.Genes (Basel). 2024 Jan 10;15(1):85. doi: 10.3390/genes15010085. Genes (Basel). 2024. PMID: 38254974 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources